Top Line: Simul has sparked critical thinking about the realized clinical benefit of simultaneous integrated boosts (SIB) for head and neck cancer.
The Study:Recognizing the undeniable ease of creating a single SIB plan that more easily meets constraints due to integrating dose fall-off across prescription volumes, he rightly points to a lack of prospective trials with validated clinical endpoints to assuage theoretical concerns of prolonged dose exposure to large swaths of elective volumes. Leave it to India to fill in the gaps. A single-center prospective randomized trial compared sequential versus SIB plans across 66 patients receiving definitive chemoradiation for locally-advanced head and neck mucosal squamous cell carcinoma. Sequential plans delivered 2 Gy x 25 = 50 Gy to gross tumor + elective volumes followed by 2 Gy x 10 = 20 Gy to gross tumor, while SIB plans delivered 1.8 Gy x 30 = 50.4 Gy to elective volumes and 2.2 Gy x 30 = 66 Gy to gross tumor. All patients received weekly cisplatin 40 mg/m2. There was no difference in cancer control or survival. Dosimetrically, both approaches delivered comparable target coverage, though SIB plans had numerically lower OAR doses, significantly lower mandible dose, and a strong trend towards lower parotid dose. Acute AE profiles were largely similar, except for a notable significant increase in grade 3+ dysphagia with SIB (46% vs 24%), which the authors hypothesize may have been due to prolonged dose exposure to swallowing structures. Importantly, this appeared to translate to numerically more treatment delays of 7+ days in the SIB (33%) versus sequential (18%) arm. Though this trial is small and didn’t have an apples-to-apples dose comparison, it provides results similar to two randomized trials that preceded it.
TBL: This study did not find substantial differences in outcomes or overall adverse effects between a sequential boost technique and simultaneous integrated boost technique for HNSCC. Nevertheless, it’s fodder for debate on the potential benefits of sequential boosts for head and neck cancers, namely possibly lower AEs and built-in adaptive replanning for the gross tumor volume. | Skidar, J Cancer Res Ther 2026
The Study:Recognizing the undeniable ease of creating a single SIB plan that more easily meets constraints due to integrating dose fall-off across prescription volumes, he rightly points to a lack of prospective trials with validated clinical endpoints to assuage theoretical concerns of prolonged dose exposure to large swaths of elective volumes. Leave it to India to fill in the gaps. A single-center prospective randomized trial compared sequential versus SIB plans across 66 patients receiving definitive chemoradiation for locally-advanced head and neck mucosal squamous cell carcinoma. Sequential plans delivered 2 Gy x 25 = 50 Gy to gross tumor + elective volumes followed by 2 Gy x 10 = 20 Gy to gross tumor, while SIB plans delivered 1.8 Gy x 30 = 50.4 Gy to elective volumes and 2.2 Gy x 30 = 66 Gy to gross tumor. All patients received weekly cisplatin 40 mg/m2. There was no difference in cancer control or survival. Dosimetrically, both approaches delivered comparable target coverage, though SIB plans had numerically lower OAR doses, significantly lower mandible dose, and a strong trend towards lower parotid dose. Acute AE profiles were largely similar, except for a notable significant increase in grade 3+ dysphagia with SIB (46% vs 24%), which the authors hypothesize may have been due to prolonged dose exposure to swallowing structures. Importantly, this appeared to translate to numerically more treatment delays of 7+ days in the SIB (33%) versus sequential (18%) arm. Though this trial is small and didn’t have an apples-to-apples dose comparison, it provides results similar to two randomized trials that preceded it.
TBL: This study did not find substantial differences in outcomes or overall adverse effects between a sequential boost technique and simultaneous integrated boost technique for HNSCC. Nevertheless, it’s fodder for debate on the potential benefits of sequential boosts for head and neck cancers, namely possibly lower AEs and built-in adaptive replanning for the gross tumor volume. | Skidar, J Cancer Res Ther 2026